PHILADELPHIA, PA — Keiretsu Forum Mid-Atlantic, South-East, and Texas regions (K4-MST) have finalized their detailed due diligence for PortIO Corp., a medical technology company developing a groundbreaking implantable vascular access device. This milestone positions PortIO for additional investment opportunities, with due diligence materials now accessible to accredited investors, family offices, and venture capitalists through Keiretsu’s Dealum database.
The device, named PortIO, represents a significant advancement in vascular access technology. Designed for long-term implantation, PortIO eliminates the need for regular maintenance such as flushing and addresses common issues associated with traditional vascular access devices, including blood clot blockages, bloodstream infections, and challenges with vein accessibility. Its innovative features align with an estimated market opportunity exceeding $2 billion, making it a valuable solution for multiple clinical settings, including emergency care, inpatient services, and home treatments.
PortIO has undergone extensive validation, including successful cadaver, animal, and clinical trials. To date, the company has secured approximately $9 million in funding and completed an initial human study without complications, adverse events, or device malfunctions. The device is now on track for its first FDA approval under the de novo pathway, supported by thorough guidance from the FDA.
“This technology exemplifies the potential to reshape long-term vascular access care,” said Paul Gianneschi of Hatch Medical, a partner in the PortIO project and member of K4-MST. Gianneschi highlighted Keiretsu Forum’s capability in advancing early-stage medical ventures, calling PortIO’s development a product of collaboration between innovative healthcare stakeholders.
Dr. Lishan Aklog, Chairman and CEO of PortIO Corp., expressed confidence in the partnership with Keiretsu Forum, emphasizing their rigorous approach to due diligence. “Keiretsu provided the expertise and resources needed to align PortIO with its path toward market success,” he stated.
The completion of due diligence marks a pivotal moment for PortIO, opening doors for significant investment in a technology poised to meet an urgent clinical need. Investors within and beyond the Keiretsu network can explore this opportunity through the detailed materials now available.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.